Business
US Patent Grant for TYK2/JAK1 Anticancer Candidate
US Patent Grant for TYK2/JAK1 Anticancer Candidate.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8256K\n Sareum Holdings PLC\n 07 January 2021\n \n \n \n \n SAREUM HOLDINGS PLC\n \n \n (\"Sareum\" or the \"Company\")\n \n \n US Patent Formally Granted for Sareum's SDC-1802 TYK2/JAK1 Inhibitor\n \n \n Cambridge, UK, 7 January 2021\n - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to announce that, further to its announcement of 8 October 2020, the United States Patent and Trademark Office has now formally approved its patent application (US Patent Application no. 16/351,620), in respect of an invention associated with Sareum's proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme (the \"SDC-1802 Programme\"). This programme is in preclinical development and targets cancer and cancer immunotherapy.\n \n \n \n Following the grant of this patent (US 10,882,829), Sareum has patent protection for the SDC-1802 molecule and pharmaceutical preparations thereof in the US and across all major territories in Europe, Japan and China. \n \n \n Sareum's CSO, Dr John Reader, commented\n : \n \n \n \"The granting of this patent in the US completes the protection of the intellectual property for our proprietary SDC-1802 Programme across all major markets. The Board believes that the patent will enhance the value of its TYK2/JAK1 inhibitor programmes and the Company's negotiating position as it continues to engage in discussions with potential licence partners.\"\n \n \n \n For further information, please contact:\n \n \n \n \n \n Sareum Holdings plc\n \n \n Tim Mitchell, CEO\n \n \n \n \n \n \n \n \n \n \n 01223 497 700\n \n \n \n \n \n \n Strand Hanson Limited (Nominated Adviser)\n \n \n James Dance / J\n ames Bellman\n \n \n \n \n \n \n \n \n \n \n 020 7409 3494\n \n \n \n \n \n \n Hybridan LLP (Nominated Broker)\n \n \n Claire Noyce / John Beresford-Peirse\n \n \n \n \n \n \n \n \n \n \n 020 3764 2341\n \n \n \n \n \n \n Citigate Dewe Rogerson (Financial PR)\n \n \n Mark Swallow/ David Dible\n \n \n \n \n \n \n \n 020 7638 9571\n \n \n \n \n \n \n \n \n About Sareum\n \n \n Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer ...